Accueil   Diary - News   All news Valneva and BliNK Therapeutics Announce Launch of New Biotech Company in Innovative Antibody Discovery

Valneva and BliNK Therapeutics Announce Launch of New Biotech Company in Innovative Antibody Discovery

European biotechnology company Valneva SE and UK company BliNK Therapeutics Ltd announced the creation of a private company specialized in the discovery of innovative monoclonal antibodies to be headquartered in Lyon, France and to be named BliNK Biomedical SAS. The new company, which will benefit from the combination of two validated antibody discovery platforms, BliNK Therapeutics Ltd’s IVV and Valneva’s VIVA|Screen®, has already secured its first round of financing.

 

Read the press release

 

 

 

Valneva